Related Experiment Video
Updated: Apr 3, 2026
06:10
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
Published on: May 9, 2025
1.1K
Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells
Jesus F San Miguel1, Bruno Paiva1, Juan-Jose Lasarte1
1Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.
Cancer Cell
|September 17, 2015
Summary
New York ESO-1 (NY-ESO-1) T-cell receptor (TCR) engineered T-cells show promise for multiple myeloma. These cells traffic to bone marrow, persist, are well-tolerated, and yield good response rates post-transplantation.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- NY-ESO-1 is a tumor antigen found in multiple myeloma.
- TCR-engineered T-cells are a promising immunotherapy approach.
- Previous studies showed activity in solid tumors.
Purpose of the Study:
- To evaluate the safety and efficacy of NY-ESO-1 TCR-engineered T-cells in multiple myeloma patients.
- To assess the trafficking, persistence, and tolerability of these cells in the bone marrow.
Main Methods:
- Patients received NY-ESO-1 TCR-engineered T-cells after stem cell transplantation.
- Evaluation of T-cell trafficking to bone marrow.
- Monitoring of T-cell persistence and patient tolerability.
- Assessment of response rates.
Main Results:
- NY-ESO-1 TCR-engineered T-cells successfully trafficked to and persisted in the bone marrow.
- The treatment was well-tolerated by patients.
- Promising response rates were observed post-infusion.
Conclusions:
- NY-ESO-1 TCR-engineered T-cells are a safe and effective treatment option for multiple myeloma.
- These cells demonstrate favorable pharmacokinetics and clinical activity in the bone marrow.
- Further investigation in larger trials is warranted.
Related Concept Videos
01:27Tumor Immunotherapy
2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:31Hybridoma Technology
18.5K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.5K